Deliver Your News to the World

Genzyme Commends New Book for Portraying Challenges Faced by Patients with Pompe Disease and Their Families


August 31, 2006 - Genzyme Corporation today welcomed publication of “The Cure,” a new book by Geeta Anand that reveals for the general public the enormous challenges faced by patients and families struggling with Pompe disease, a very rare and potentially fatal inherited disorder. In addition, the book portrays the extraordinary commitment of scientists, physicians, patient associations and companies involved in Pompe research.

Ms. Anand’s narrative also highlights the risks, setbacks and difficulty of the drug development process and underscores the perseverance and massive investment required to bring a drug toward approval.

“The Cure” profiles John Crowley, the father of two children with Pompe disease, who became increasingly involved in the Pompe research community in the late 1990s, in an effort to enroll his children in a clinical trial. John subsequently served as chief executive of Novazyme Pharmaceuticals, and following Genzyme’s acquisition of Novazyme, led the company’s Pompe program from September 2001-December 2002.

“The remarkable energy and determination shown by John and his wife Aileen to help their children reflects the courage and commitment displayed by all parents of children with Pompe and other rare diseases,” said Edward Kaye, M.D., vice president of clinical research for Genzyme. “We hope this book will raise awareness of Pompe disease, and we are excited that the general public will get a glimpse of the unheralded people and institutions throughout the Pompe community who have worked for many years in the difficult quest to develop a treatment for this disease.”

For more information about Pompe disease, please visit

About Genzyme

One of the world’s leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. This year marks the 25th anniversary of Genzyme’s founding. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 8,500 employees in locations spanning the globe and 2005 revenues of $2.7 billion. Genzyme has been selected by FORTUNE as one of the “100 Best Companies to Work for” in the United States.

With many established products and services helping patients in more than 80 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company’s products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune diseases, and diagnostic testing. Genzyme’s commitment to innovation continues today with a substantial development program focused on these fields, as well as heart disease and other areas of unmet medical need.


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.